Anti Glaucoma Eyedrops Sales

Anti Glaucoma Eyedrops Sales Market Outlook

The global anti-glaucoma eyedrops market is anticipated to reach approximately USD 10.5 billion by 2035, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period from 2025 to 2035. This growth is primarily driven by an increase in the prevalence of glaucoma and other eye disorders, which are becoming more common due to aging populations and lifestyle changes. Furthermore, advancements in drug formulation and delivery techniques, including the development of novel compounds and the enhancement of existing ingredients, are expected to bolster market growth. The rising awareness of eye health and increased healthcare expenditure are also contributing factors that will support market expansion. Additionally, the growing availability of online pharmacies is making these medications more accessible, further driving demand.

Growth Factor of the Market

One of the key growth factors for the anti-glaucoma eyedrops market is the escalating incidence of glaucoma, a condition that affects millions worldwide and can lead to irreversible blindness if not treated promptly. As populations age, the number of individuals at risk for developing glaucoma is on the rise, which is driving demand for effective treatment options. Moreover, increased healthcare initiatives aimed at screening and early detection of glaucoma are leading to higher diagnosis rates, which in turn fuels the demand for anti-glaucoma medications. The development of innovative therapies, such as fixed-dose combinations and sustained-release formulations, has also improved treatment adherence among patients, thereby expanding the market. Additionally, advancements in technology and pharmaceutical research are fostering the emergence of new product types, enhancing the portfolio of available treatments. Lastly, the growing trend toward preventive healthcare and patient education about glaucoma management creates further opportunities for market growth.

Key Highlights of the Market

• The global anti-glaucoma eyedrops market is projected to grow at a CAGR of 5.8% from 2025 to 2035.
• Increasing prevalence of glaucoma, particularly among the aging population, is a major driver of market growth.
• Technological advancements in drug formulations are leading to the development of more effective treatment options.
• The shift towards online pharmacies is enhancing the accessibility of anti-glaucoma medications.
• Rising healthcare expenditure and awareness about eye health contribute positively to market demand.

By Product Type

Beta Blockers:

Beta blockers are one of the most widely prescribed classes of medications for treating glaucoma, specifically open-angle glaucoma. They work by reducing the production of aqueous humor in the eye, thereby lowering intraocular pressure (IOP). Commonly used beta blockers include Timolol and Betaxolol. The effectiveness of these drugs, coupled with their established safety profiles, makes them a preferred choice among healthcare providers. Additionally, the affordable pricing of beta blockers contributes to their widespread use, especially in developing countries where healthcare costs may be a concern. The ongoing research to enhance their formulation and combination therapies may further bolster their presence in the market.

Prostaglandins:

Prostaglandins have gained significant traction in the anti-glaucoma medication landscape due to their efficacy in increasing the outflow of aqueous humor, which effectively lowers IOP. Drugs such as Latanoprost and Travoprost belong to this category and are often preferred by ophthalmologists because of their once-daily dosing regimen, which improves patient compliance. The introduction of new formulations that minimize side effects and enhance patient tolerance is expected to drive the growth of this segment. As more patients are diagnosed with glaucoma, the demand for prostaglandin medications is likely to increase, making this segment a crucial contributor to the overall market.

Alpha Agonists:

Alpha agonists, such as Brimonidine, are another important category in the anti-glaucoma eyedrops market. They function by both reducing aqueous humor production and increasing uveoscleral outflow, which helps decrease IOP. These medications are especially beneficial for patients who may not tolerate beta blockers due to systemic side effects. Although alpha agonists represent a smaller share of the market compared to beta blockers and prostaglandins, their unique mechanism of action and ability to be used in combination therapy are driving their adoption. Continuous research and development are expected to enhance their formulations and expand their applications, especially in patients with complex glaucoma cases.

Carbonic Anhydrase Inhibitors:

Carbonic anhydrase inhibitors, including Dorzolamide, work by inhibiting the enzyme carbonic anhydrase, which plays a crucial role in the production of aqueous humor. By reducing the production of this fluid, these medications effectively lower IOP. This class of drugs is often used in conjunction with other medications for additive effects, particularly in patients experiencing inadequate control with monotherapy. The segment is characterized by a moderate growth rate, supported by expanding clinical applications and the integration of these inhibitors into combination therapies. Ongoing advancements in formulation technologies are likely to further enhance their appeal in the anti-glaucoma treatment landscape.

Rho Kinase Inhibitors:

Rho kinase inhibitors, such as Netarsudil, represent a newer class of anti-glaucoma medications that have garnered interest due to their unique mechanism of action. They work by enhancing the outflow of aqueous humor through the trabecular meshwork, thus effectively lowering IOP. The introduction of Rho kinase inhibitors has provided healthcare providers with additional options for patients who do not achieve adequate control with traditional therapies. As clinical data supporting the safety and efficacy of these agents continue to emerge, they are expected to gain market share, particularly among patients with advanced or treatment-resistant glaucoma.

By Application

Open-angle Glaucoma:

Open-angle glaucoma is the most prevalent form of glaucoma and is characterized by a gradual increase in intraocular pressure. This condition often goes unnoticed until significant damage occurs, making early intervention critical. Anti-glaucoma eyedrops are first-line treatments for managing open-angle glaucoma, as they effectively lower IOP, preventing further optic nerve damage. The demand for medications targeting this condition is particularly robust, driven by the high prevalence of open-angle glaucoma among older adults and the need for long-term management strategies. Ongoing advancements in drug delivery systems and treatment formulations are expected to enhance the effectiveness of therapies in this segment.

Angle-closure Glaucoma:

Angle-closure glaucoma is less common but can lead to rapid vision loss if not treated promptly. It occurs when the drainage angle of the eye becomes blocked, resulting in a sudden increase in IOP. Anti-glaucoma medications are often used in conjunction with surgical interventions to manage acute angle-closure glaucoma. The urgency associated with this condition necessitates effective and rapid treatments, which is driving market growth in this application segment. Increased awareness and regular screening for at-risk populations also contribute to the rising demand for suitable medications.

Normal-tension Glaucoma:

Normal-tension glaucoma is characterized by optic nerve damage despite normal IOP levels. This condition presents unique challenges for treatment, as traditional anti-glaucoma medications may not be effective. However, recent advancements in pharmacotherapy, including the development of neuroprotective agents and alternative treatment strategies, are leading to new options for patients. As research progresses and new therapies are validated, the normal-tension glaucoma segment is expected to see growth in demand, highlighting the need for tailored approaches to managing this complex condition.

Secondary Glaucoma:

Secondary glaucoma can arise from various conditions, including inflammation, trauma, or the use of certain medications. The management of secondary glaucoma often requires a multifaceted approach, including the use of specific anti-glaucoma eyedrops tailored to the underlying cause. The complexity of this form of glaucoma drives an increasing demand for specialized treatment options, making it a significant segment within the market. As awareness of secondary glaucoma grows, along with advancements in targeted therapies, the segment is projected to grow steadily in the coming years.

Congenital Glaucoma:

Congenital glaucoma is a rare but serious condition that is present at birth and often requires prompt intervention to prevent vision loss. Anti-glaucoma eyedrops are essential for managing IOP in affected infants and children. The segment is characterized by a niche market with unique challenges, including the need for pediatric formulations and consideration of safety profiles in young patients. Increased efforts to improve early diagnosis and treatment accessibility for congenital glaucoma are expected to drive demand for specific medications tailored to this population.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of anti-glaucoma eyedrops, especially for patients requiring immediate care or those undergoing surgical interventions. Medications dispensed through hospital pharmacies often include a range of therapeutic options that are available on-site, allowing healthcare providers to offer timely treatments. The integration of pharmacy services within hospitals facilitates patient education and adherence support, enhancing treatment outcomes. Furthermore, hospital pharmacies are critical in managing complex cases of glaucoma, where physicians may require specialized medications that are not readily available in retail settings.

Retail Pharmacies:

Retail pharmacies are a primary distribution channel for anti-glaucoma medications, catering to patients who require ongoing treatment for glaucoma management. These pharmacies provide convenience and accessibility, allowing patients to easily refill prescriptions and consult with pharmacists about their medications. The presence of retail pharmacies across various geographic locations ensures that patients have access to essential therapies. Additionally, the growing trend of offering patient support programs and educational resources within retail pharmacies contributes positively to patient adherence and management of their condition.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for anti-glaucoma eyedrops, particularly in light of the increasing trend toward digital healthcare solutions. The availability of these medications through online platforms offers patients convenience, discretion, and often competitive pricing. This channel is especially beneficial for individuals with mobility issues or those living in remote areas, ensuring they can access necessary treatments without barriers. Additionally, the pandemic highlighted the importance of telehealth and online pharmacies, further accelerating their adoption. As regulations governing online pharmacies continue to evolve, the potential for growth in this segment remains substantial.

By Ingredient Type

Brimonidine:

Brimonidine is an alpha agonist used primarily for the treatment of open-angle glaucoma and ocular hypertension. It works by reducing aqueous humor production and increasing uveoscleral outflow, making it a valuable option in managing intraocular pressure. Due to its targeted action and relatively low side effect profile, Brimonidine has gained popularity among clinicians and patients alike. Ongoing research into its effectiveness in combination therapies is likely to enhance its usage in glaucoma management, thus driving growth in the segment.

Travoprost:

Travoprost, a prostaglandin analog, is widely utilized in the management of glaucoma due to its ability to effectively lower intraocular pressure by enhancing aqueous humor outflow. The drug's once-daily dosing regimen significantly improves patient adherence compared to other treatments requiring more frequent administration. Travoprost's favorable safety profile and efficacy have made it a preferred choice for many practitioners, contributing to its strong market presence. The continuous development of new formulations and combination therapies is expected to further bolster its market share.

Latanoprost:

Latanoprost is another prominent prostaglandin analog that is recognized for its effectiveness in lowering IOP through enhanced aqueous humor drainage. Its wide acceptance among healthcare providers stems from its proven efficacy and safety across diverse patient populations. Latanoprost often serves as a first-line treatment for open-angle glaucoma and ocular hypertension, making it one of the best-selling anti-glaucoma medications globally. The ongoing efforts to develop additional formulations aimed at reducing side effects and enhancing compliance are likely to strengthen its position in the market.

Dorzolamide:

Dorzolamide, a carbonic anhydrase inhibitor, is utilized primarily for reducing aqueous humor production, making it effective in lowering IOP in patients with glaucoma. It is often used in combination with other therapies to achieve better intraocular pressure control. The advantage of Dorzolamide lies in its unique mechanism of action, which provides a complementary approach to traditional treatment regimens. Its use in special populations, such as those intolerant to beta blockers, further expands its market presence, as does the ongoing research into its potential applications in diverse glaucoma scenarios.

Netarsudil:

Netarsudil, a Rho kinase inhibitor, has recently entered the anti-glaucoma market, offering a novel mechanism of action by enhancing aqueous humor outflow through the trabecular meshwork. This unique feature has positioned Netarsudil as an important addition to the treatment options available for glaucoma patients. The growing body of clinical evidence supporting its safety and efficacy in lowering IOP is helping to drive its adoption among healthcare providers. As the market for Rho kinase inhibitors evolves, Netarsudil is expected to play a significant role in the future of glaucoma management, particularly in patients with complex or treatment-resistant disease.

By Region

In North America, the anti-glaucoma eyedrops market is robust, driven by a high prevalence of glaucoma and significant healthcare expenditure. The region is expected to maintain its dominant position, accounting for approximately 40% of the global market share in 2035, with a CAGR of around 6.0% from 2025 to 2035. The presence of advanced healthcare infrastructure, coupled with increased awareness of eye health, contributes to the strong demand for anti-glaucoma medications. Furthermore, the growing trend towards telemedicine and online pharmacies is expected to enhance accessibility to these therapies, driving additional growth in the region.

In Europe, the anti-glaucoma eyedrops market is projected to experience steady growth, driven by similar factors influencing the North American market. The region is expected to account for approximately 30% of the global market by 2035. The aging population, coupled with increased initiatives for early glaucoma detection and treatment, is expected to support market expansion. Along with this, favorable reimbursement policies for anti-glaucoma medications further encourage patient adherence to prescribed therapies. As the market dynamics evolve, the increased focus on personalized medicine and advanced treatment strategies is anticipated to create additional growth opportunities in Europe.

Opportunities

The anti-glaucoma eyedrops market presents numerous opportunities, particularly in the realm of research and development. Advances in drug delivery systems, such as sustained-release formulations and innovative delivery methods, could significantly enhance patient adherence and treatment efficacy. As the demand for personalized medicine grows, there is ample scope for developing tailored therapies that meet the specific needs of various patient populations, including pediatric and geriatric groups. Additionally, as awareness surrounding eye health and glaucoma management continues to rise, there is an opportunity for pharmaceutical companies to invest in educational programs that promote regular eye screenings and the importance of timely treatment. The emergence of telehealth and online pharmacy services further enables increased access and convenience for patients, presenting a lucrative market opportunity for both established and emerging players.

Another avenue for growth in the anti-glaucoma eyedrops market lies in exploring combination therapies that pair existing medications with new agents to improve IOP management. By leveraging the unique mechanisms of action of different drug classes, healthcare providers can create more effective treatment regimens for patients facing challenges in controlling their glaucoma. Additionally, expanding into emerging markets where glaucoma prevalence is rising but treatment options may be limited presents a significant opportunity for growth. Companies that can navigate regulatory hurdles and establish strong distribution networks in these regions stand to benefit from the increasing demand for effective glaucoma therapies. Overall, the combination of innovation, education, and market expansion can drive significant opportunities in the anti-glaucoma eyedrops market.

Threats

Despite the promising growth prospects for the anti-glaucoma eyedrops market, several threats could impede its progress. One significant concern is the increasing competition from generic medications, which may lead to pricing pressures and reduced profit margins for branded products. As patents for major anti-glaucoma drugs expire, generic alternatives may flood the market, making it challenging for established companies to maintain their market share. This scenario may particularly affect smaller pharmaceutical firms that rely heavily on a limited product portfolio. Additionally, the growing trend toward value-based care may compel healthcare providers to seek more cost-effective treatment options, further complicating the market dynamics.

Another threat facing the anti-glaucoma eyedrops market is the potential for regulatory challenges and scrutiny surrounding drug approvals and safety. As the pharmaceutical industry faces increasing pressure to demonstrate the safety and efficacy of new treatments, any delays or setbacks in the approval process could hinder potential market entries. Furthermore, the ongoing shifts in healthcare policies and regulations, particularly in response to the COVID-19 pandemic, may create uncertainties for pharmaceutical companies regarding pricing, reimbursement, and distribution strategies. Such challenges necessitate adaptability and strategic planning to mitigate risks within the competitive landscape.

Competitor Outlook

• Allergan
• Merck & Co.
• Novartis
• Pfizer
• Bausch + Lomb
• Otsuka Pharmaceutical
• Teva Pharmaceutical Industries
• Akorn Pharmaceutical
• Santen Pharmaceutical
• Hikma Pharmaceuticals
• Sun Pharmaceutical Industries
• Laboratoires Thea
• UCB Pharma
• Aerie Pharmaceuticals
• Lumenis

The competitive landscape of the anti-glaucoma eyedrops market is characterized by a mix of established pharmaceutical companies and emerging players striving to capture market share. Major players, such as Allergan, Novartis, and Merck & Co., dominate the market with their extensive portfolios of anti-glaucoma medications, established brand recognition, and strong distribution networks. These companies invest heavily in research and development to bring innovative therapies to market, ensuring they remain at the forefront of treatment options for glaucoma. Their expertise in navigating regulatory pathways and established relationships with healthcare providers further enhance their competitive advantage.

Emerging companies, such as Aerie Pharmaceuticals and Lumenis, are also making significant strides in the anti-glaucoma market by introducing novel products and leveraging cutting-edge technology. These companies often focus on niche areas within the market, targeting unmet medical needs and developing specialized formulations to address specific patient populations. The competitive dynamics between established players and newer entrants foster an environment of innovation and drive improvements in treatment efficacy, ultimately benefiting patients.

Key players like Teva Pharmaceutical and Bausch + Lomb are also working to expand their global footprint through strategic collaborations, partnerships, and acquisitions. These initiatives allow companies to enhance their product offerings, access new markets, and strengthen their supply chains. As the market continues to evolve, the emphasis on personalized medicine and patient-centric approaches will shape future competitive strategies, allowing companies to differentiate themselves in a crowded marketplace. The ability to adapt to shifting market trends and regulatory landscapes will be crucial for maintaining a strong competitive position in the anti-glaucoma eyedrops market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Pfizer
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Lumenis
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Allergan
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 UCB Pharma
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Merck & Co.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Bausch + Lomb
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Laboratoires Thea
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Akorn Pharmaceutical
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Aerie Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hikma Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Otsuka Pharmaceutical
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Santen Pharmaceutical
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Anti Glaucoma Eyedrops Sales Market, By Application
    • 6.1.1 Open-angle Glaucoma
    • 6.1.2 Angle-closure Glaucoma
    • 6.1.3 Normal-tension Glaucoma
    • 6.1.4 Secondary Glaucoma
    • 6.1.5 Congenital Glaucoma
  • 6.2 Anti Glaucoma Eyedrops Sales Market, By Product Type
    • 6.2.1 Beta Blockers
    • 6.2.2 Prostaglandins
    • 6.2.3 Alpha Agonists
    • 6.2.4 Carbonic Anhydrase Inhibitors
    • 6.2.5 Rho Kinase Inhibitors
  • 6.3 Anti Glaucoma Eyedrops Sales Market, By Ingredient Type
    • 6.3.1 Brimonidine
    • 6.3.2 Travoprost
    • 6.3.3 Latanoprost
    • 6.3.4 Dorzolamide
    • 6.3.5 Netarsudil
  • 6.4 Anti Glaucoma Eyedrops Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Anti Glaucoma Eyedrops Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Anti Glaucoma Eyedrops Sales market is categorized based on

By Product Type

• Beta Blockers
• Prostaglandins
• Alpha Agonists
• Carbonic Anhydrase Inhibitors
• Rho Kinase Inhibitors

By Application

• Open-angle Glaucoma
• Angle-closure Glaucoma
• Normal-tension Glaucoma
• Secondary Glaucoma
• Congenital Glaucoma

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Brimonidine
• Travoprost
• Latanoprost
• Dorzolamide
• Netarsudil

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Allergan
• Merck & Co.
• Novartis
• Pfizer
• Bausch + Lomb
• Otsuka Pharmaceutical
• Teva Pharmaceutical Industries
• Akorn Pharmaceutical
• Santen Pharmaceutical
• Hikma Pharmaceuticals
• Sun Pharmaceutical Industries
• Laboratoires Thea
• UCB Pharma
• Aerie Pharmaceuticals
• Lumenis